GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 17,179 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 17,179 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $76.80, for a total value of $1,319,347.20. Following the completion of the transaction, the chief executive officer owned 58,447 shares in the company, valued at approximately $4,488,729.60. The trade was a 22.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total value of $2,001,331.99.
• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The stock was sold at an average price of $94.00, for a total value of $155,382.00.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $75.50 on Wednesday. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The stock’s 50 day moving average is $93.95 and its 200-day moving average is $120.00. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -100.67 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. The business had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. Sell-side analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on WGS. Zacks Research upgraded shares of GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 25th. Wells Fargo & Company upgraded shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price on the stock in a report on Monday, February 9th. Jefferies Financial Group set a $150.00 price target on shares of GeneDx in a research report on Monday, February 23rd. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, BTIG Research decreased their price objective on GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $150.71.

Institutional Trading of GeneDx

Institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC bought a new position in shares of GeneDx in the third quarter valued at approximately $48,157,000. Rhumbline Advisers lifted its holdings in GeneDx by 42.7% during the second quarter. Rhumbline Advisers now owns 27,610 shares of the company’s stock worth $2,549,000 after acquiring an additional 8,258 shares during the period. Principal Financial Group Inc. lifted its holdings in GeneDx by 340.4% during the third quarter. Principal Financial Group Inc. now owns 59,624 shares of the company’s stock worth $6,424,000 after acquiring an additional 46,085 shares during the period. Impax Asset Management Group plc purchased a new position in GeneDx in the third quarter worth $5,387,000. Finally, Telemark Asset Management LLC purchased a new position in GeneDx in the third quarter worth $12,929,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.